Else Marie Bartels
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Else Marie Bartels has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Henning Bliddal
The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark
4 shared publications - Robin Christensen
The Parker Institute: MSU, Copenhagen University Hospital, Frederiksberg, Copenhagen, Denmark
3 shared publications - Bente Danneskiold-Samsøe
Faculty of Health Science, University of Copenhagen, Copenhagen, Denmark
2 shared publications - Henrik Gudbergsen
The Parker Institute, Copenhagen University Hospital - Bispebjerg & Frederiksberg, Copenhagen, Denmark
2 shared publications - Søren Ribel-Madsen
Department of Orthopaedic Surgery, Bispebjerg and Frederiksberg University Hospital, Frederiksberg, Denmark
2 shared publications - Anders Woetmann
LEO Foundation Skin Immunology Research Center, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark
1 shared publication
Latest Publications
- Open Access
- 22 March 2013
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 14 (1) , 1-9
Changes in bone marrow lesions in response to weight-loss in obese knee osteoarthritis patients: a prospective cohort study
Background: Patients are susceptible for knee osteoarthritis (KOA) with increasing age and obesity and KOA is expected to become a major disabling disease in the future. An important feature of KOA on magnetic resonance imaging (MRI) is changes in the subchondral bone, bone marrow lesions (BMLs), which are related to the future degeneration of the knee joint as well as prevalent clinical symptoms. The aim of this study was to investigate the changes in BMLs after a 16-week weight-loss period in obese subjects with KOA and relate changes in BMLs to the effects of weight-loss on clinical symptoms. Methods: This prospective cohort study included patients with a body mass index ≥ 30 kg/m2, an age ≥ 50 years and primary KOA. Patients underwent a 16 weeks supervised diet program which included formula products and dietetic counselling (ClinicalTrials.gov: NCT00655941). BMLs in tibia and femur were assessed on MRI before and after the weight-loss using the Boston-Leeds Osteoarthritis Knee Score. Response to weight-loss in BML scores was dichotomised to patients experiencing a decrease in BML scores (responders) and patients who did not (non-responders). The association of BMLs to weight-loss was assessed by logistic regressions and correlation analyses. Results: 39 patients (23%) were classified as responders in the sum of all BML size scores whereas 130 patients (77%) deteriorated or remained stable and were categorized as non-responders. Logistic regression analyses revealed no association between weight-loss < or ≥ 10% and response in BMLs in the most affected compartment (OR 1.86 [CI 0.66 to 5.26, p=0.24]). There was no association between weight-loss and response in maximum BML score (OR 1.13 [CI 0.39 to 3.28, p=0.81]). The relationship between changes in BMLs and clinical symptoms revealed that an equal proportion of patients classified as BML responders and non-responders experienced an OMERACT-OARSI response (69 vs. 71%, p=0.86). Conclusions: Weight-loss did not improve the sum of tibiofemoral BML size scores or the maximum tibiofemoral BML score, suggesting that BMLs do not respond to a rapidly decreased body weight. The missing relationship between clinical symptoms and BMLs calls for further investigation.
- 22 March 2013
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 14 (1) , 1-9
Open AccessChanges in bone marrow lesions in response to weight-loss in obese knee osteoarthritis patients: a prospective cohort study
Background: Patients are susceptible for knee osteoarthritis (KOA) with increasing age and obesity and KOA is expected to become a major disabling disease in the future. An important feature of KOA on magnetic resonance imaging (MRI) is changes in the subchondral bone, bone marrow lesions (BMLs), which are related to the future degeneration of the knee joint as well as prevalent clinical symptoms. The aim of this study was to investigate the changes in BMLs after a 16-week weight-loss period in obese subjects with KOA and relate changes in BMLs to the effects of weight-loss on clinical symptoms. Methods: This prospective cohort study included patients with a body mass index ≥ 30 kg/m2, an age ≥ 50 years and primary KOA. Patients underwent a 16 weeks supervised diet program which included formula products and dietetic counselling (ClinicalTrials.gov: NCT00655941). BMLs in tibia and femur were assessed on MRI before and after the weight-loss using the Boston-Leeds Osteoarthritis Knee Score. Response to weight-loss in BML scores was dichotomised to patients experiencing a decrease in BML scores (responders) and patients who did not (non-responders). The association of BMLs to weight-loss was assessed by logistic regressions and correlation analyses. Results: 39 patients (23%) were classified as responders in the sum of all BML size scores whereas 130 patients (77%) deteriorated or remained stable and were categorized as non-responders. Logistic regression analyses revealed no association between weight-loss < or ≥ 10% and response in BMLs in the most affected compartment (OR 1.86 [CI 0.66 to 5.26, p=0.24]). There was no association between weight-loss and response in maximum BML score (OR 1.13 [CI 0.39 to 3.28, p=0.81]). The relationship between changes in BMLs and clinical symptoms revealed that an equal proportion of patients classified as BML responders and non-responders experienced an OMERACT-OARSI response (69 vs. 71%, p=0.86). Conclusions: Weight-loss did not improve the sum of tibiofemoral BML size scores or the maximum tibiofemoral BML score, suggesting that BMLs do not respond to a rapidly decreased body weight. The missing relationship between clinical symptoms and BMLs calls for further investigation.
Differential effects of decoy receptor‐ and antibody‐mediated tumour necrosis factor blockage on FoxP3 expression in responsive arthritis patients
Our aim was to clarify if anti‐tumour necrosis factor (TNF) drugs have effect on expression of three splice forms of FoxP3 mRNA in blood CD4+ T cells from rheumatoid arthritis (RA) patients compared with healthy controls. Forty‐five rheumatoid arthritis patients treated with anti‐TNF therapy were investigated in a 12‐week prospective cohort study. FoxP3 isoforms, CD25 and CTLA‐4 mRNA in blood CD4+ T cells were measured with quantitative real‐time PCR. Patients benefitting from the treatment, based on changes in DAS28 scores, revealed a significant decrease in expression of full‐length FoxP3 following 12 weeks treatment with TNF receptor 2 fusion protein (Etanercept), but not following treatment with anti‐TNF antibodies (Adalimumab or Infliximab). A partial normalization of the CTLA‐4/FoxP3fl ratio and a correlation between clinical improvement and change in FoxP3 mRNA expression were also seen in Etanercept responders. These changes were not observed in responsive patients treated with the antibody therapies. Our data suggest that TNF decoy receptor and anti‐TNF antibodies differ in their effect on FoxP3 expression in responsive patients. As Etanercept binds both TNF‐α and Lymphotoxin‐α (LT‐α), whereas the antibodies only target TNF‐α, LT‐α may regulate FoxP3 expression in a subset of RA patients. Our findings support the view that anti‐TNF treatment is mainly symptomatic.
Differential effects of decoy receptor‐ and antibody‐mediated tumour necrosis factor blockage on FoxP3 expression in responsive arthritis patients
Our aim was to clarify if anti‐tumour necrosis factor (TNF) drugs have effect on expression of three splice forms of FoxP3 mRNA in blood CD4+ T cells from rheumatoid arthritis (RA) patients compared with healthy controls. Forty‐five rheumatoid arthritis patients treated with anti‐TNF therapy were investigated in a 12‐week prospective cohort study. FoxP3 isoforms, CD25 and CTLA‐4 mRNA in blood CD4+ T cells were measured with quantitative real‐time PCR. Patients benefitting from the treatment, based on changes in DAS28 scores, revealed a significant decrease in expression of full‐length FoxP3 following 12 weeks treatment with TNF receptor 2 fusion protein (Etanercept), but not following treatment with anti‐TNF antibodies (Adalimumab or Infliximab). A partial normalization of the CTLA‐4/FoxP3fl ratio and a correlation between clinical improvement and change in FoxP3 mRNA expression were also seen in Etanercept responders. These changes were not observed in responsive patients treated with the antibody therapies. Our data suggest that TNF decoy receptor and anti‐TNF antibodies differ in their effect on FoxP3 expression in responsive patients. As Etanercept binds both TNF‐α and Lymphotoxin‐α (LT‐α), whereas the antibodies only target TNF‐α, LT‐α may regulate FoxP3 expression in a subset of RA patients. Our findings support the view that anti‐TNF treatment is mainly symptomatic.
- Open Access
- 18 August 2011
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 12 (1) , 1-8
Test-retest of computerized health status questionnaires frequently used in the monitoring of knee osteoarthritis: a randomized crossover trial
Background: To compare data based on touch screen to data based on traditional paper versions of questionnaires frequently used to examine patient reported outcomes in knee osteoarthritis patients and to examine the impact of patient characteristics on this comparison Methods: Participants were recruited from an ongoing trial (http://ClinicalTrials.Gov Identifier: NCT00655941). 20 female participants, mean age 67 (SD 7), completed KOOS, VAS pain, function and patient global, SF-36, Physical Activity Scale, painDETECT, and the ADL Taxonomy. Patients were randomly assigned to one of two subgroups, completing either the paper or touch screen version first. Mean, mean differences (95% CI), median, median differences and Intraclass Correlation Coefficients (ICCs) were calculated for all questionnaires. Results: ICCs between data based on computerized and paper versions ranged from 0.86 to 0.99. Analysis revealed a statistically significant difference between versions of the ADL Taxonomy, but not for the remaining questionnaires. Age, computer experience or education-level had no significant impact on the results. The computerized questionnaires were reported to be easier to use. Conclusion: The computerized questionnaires gave comparable results to answers given on paper. Patient characteristics did not influence results and implementation was feasible.
- 18 August 2011
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 12 (1) , 1-8
Open AccessTest-retest of computerized health status questionnaires frequently used in the monitoring of knee osteoarthritis: a randomized crossover trial
Background: To compare data based on touch screen to data based on traditional paper versions of questionnaires frequently used to examine patient reported outcomes in knee osteoarthritis patients and to examine the impact of patient characteristics on this comparison Methods: Participants were recruited from an ongoing trial (http://ClinicalTrials.Gov Identifier: NCT00655941). 20 female participants, mean age 67 (SD 7), completed KOOS, VAS pain, function and patient global, SF-36, Physical Activity Scale, painDETECT, and the ADL Taxonomy. Patients were randomly assigned to one of two subgroups, completing either the paper or touch screen version first. Mean, mean differences (95% CI), median, median differences and Intraclass Correlation Coefficients (ICCs) were calculated for all questionnaires. Results: ICCs between data based on computerized and paper versions ranged from 0.86 to 0.99. Analysis revealed a statistically significant difference between versions of the ADL Taxonomy, but not for the remaining questionnaires. Age, computer experience or education-level had no significant impact on the results. The computerized questionnaires were reported to be easier to use. Conclusion: The computerized questionnaires gave comparable results to answers given on paper. Patient characteristics did not influence results and implementation was feasible.
- 1 March 2010
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 18 (3) , 289-296
Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials
- 1 March 2010
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 18 (3) , 289-296
Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials